Table 4. Analysis of Prognostic Factors for OS.
| Variable | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| Median OS (months) | 95% CI | p value | HR | 95% CI | p value | |
| Age (yr) | 0.001 | 1.56 | 0.84–2.88 | 0.159 | ||
| <65 | 57.8 | 40.8–75.0 | ||||
| ≥65 | 24.7 | 18.6–30.8 | ||||
| Sex | 0.429 | |||||
| Female | 56.0 | 30.8–81.2 | ||||
| Male | 44.8 | 24.9–64.7 | ||||
| BMI (kg/m2) | 0.319 | |||||
| <25 | 52.0 | 19.4–84.6 | ||||
| ≥25 | 42.1 | 23.6–60.7 | ||||
| ECOG PS | 0.483 | |||||
| 0 | 56.0 | 23.1–88.9 | ||||
| ≥1 | 48.9 | 29.1–68.7 | ||||
| Smoking history | 0.740 | |||||
| Never smoker | 49.2 | 25.8–72.6 | ||||
| Light smoker | 66.5 | 23.5–109.5 | ||||
| Heavy smoker | 44.8 | 19.8–69.8 | ||||
| Disease state | 0.102 | 1.61 | 0.91–2.86 | 0.105 | ||
| Recurrent disease | 66.5 | 43.9–89.1 | ||||
| Unresectable disease | 36.4 | 19.0–53.8 | ||||
| Intracranial metastasis, initial | 0.059 | 1.90 | 1.10–3.27 | 0.022 | ||
| No | 59.3 | 47.4–71.2 | ||||
| Yes | 32.1 | 20.7–43.5 | ||||
| Extracranial metastasis, initial | 0.124 | |||||
| No | NR | NR | ||||
| Yes | 44.8 | 28.2–61.4 | ||||
| Platinum doublet (first-line) | 0.549 | |||||
| Yes | 52.0 | 31.4–72.5 | ||||
| No | 29.4 | 0.0–64.2 | ||||
| First-line chemotherapy | 0.919 | |||||
| Pemetrexed-based | 66.5 | 22.8–110.2 | ||||
| Non-pemetrexed-based | 49.2 | 26.9–71.5 | ||||
| Pemetrexed exposure | 0.069 | 1.50 | 0.82–2.73 | 0.188 | ||
| Yes | 56.0 | 41.8–70.2 | ||||
| No | 27.7 | 18.6–36.8 | ||||
| 2nd-generation ALKi exposure | <0.001 | 2.87 | 1.61–5.10 | <0.001 | ||
| Yes | 83.7 | 46.0–121.4 | ||||
| No | 31.4 | 24.7–38.1 | ||||
OS, overall survival; CI, confidence interval; HR, hazard ratio; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); ECOG PS, Eastern Cooperative Oncology Group performance status; ALKi, anaplastic lymphoma kinase inhibitor.